On October 7, 2026 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, reported that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry.
In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories.
Oral Presentation Details
Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry
Session Title: Renal Cell Cancer and Novel Targets
Session Number: 506
Track: Clinical Oncology
Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST
Location: Hall C
Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany
Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide
Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy
Session Number: 1505
Track: Cutting Edge Science
Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST
Location: Hall B
Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France
Meet the Expert Session
Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities
Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST
Location: ITM Booth #415, Hall X4
Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM
Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST.
177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use.
About the COMPETE Trial
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs.
About Ga-DPI-4452 (ITM-94)
Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use.
(Press release, ITM Isotopen Technologien Munchen, OCT 7, 2026, View Source [SID1234673275])